Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06467344
PHASE1/PHASE2

Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)

Sponsor: Ascidian Therapeutics, Inc

View on ClinicalTrials.gov

Summary

This study is an open-label, single ascending dose clinical trial in participants who have ABCA4-related retinopathies. This is the first-in-human clinical trial in which ACDN-01 will be evaluated for safety, tolerability, and preliminary efficacy following a single subretinal injection of ACDN-01.

Official title: ACDN-01-001: Open-Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Subretinal ACDN-01 in Participants With ABCA4-related Retinopathy

Key Details

Gender

All

Age Range

12 Years - Any

Study Type

INTERVENTIONAL

Enrollment

15

Start Date

2024-06-11

Completion Date

2030-12-01

Last Updated

2025-12-02

Healthy Volunteers

No

Interventions

DRUG

ACDN-01

ACDN-01 is an AAV-based vector carrying a DNA construct encoding for an ABCA4 RNA exon editor. One time administration is via subretinal injection.

Locations (10)

University of San Francisco

San Francisco, California, United States

Vitreo Retinal Associates

Gainesville, Florida, United States

Bascom Palmer Eye Institute

Miami, Florida, United States

Wilmer Eye Institute at John Hopkins

Baltimore, Maryland, United States

Massachusetts Eye and Ear

Boston, Massachusetts, United States

University of Michigan Kellogg Eye Center

Ann Arbor, Michigan, United States

Cincinnati Eye Institute

Cincinnati, Ohio, United States

Casey Eye Institute OHSU

Portland, Oregon, United States

Retina Foundation of the Southwest

Dallas, Texas, United States

Retina Consultants of Texas

Houston, Texas, United States